Since the beginning of September,
Among other things, the Company has achieved the following during the second half of 2022:
- EU-GMP certification of Biotech Pharm1 (BP1) from the
Danish Medicines Agency - Established a strong Quality Assurance (QA) setup
-
Closed deals worth more than
DKK 80 million for its biomaterial production for the next 3 years:DKK 40 million withWEECO Pharma GmbH DKK 41 million with Storkpharm Sp. z.o.o
-
Raised additional approx.
DKK 22 million for the further development of the Company and also write-down of its current loan facility -
Approval of the Company's subsidiary
CannGros ApS and its new facilities in Ansager for even more lean production- Increasing interest and revenue in CannGros
-
Established a strong commercial department of CannGros and
DanCann Pharma for sales and business development - Established its Regulatory Affairs (RA) function in CannGros
-
Approval of its side listing on the OTCQB Venture Market in the
USA
Since its foundation in 2018,
- We are now one of a limited number of companies in our industry that have achieved this certification, which is very satisfying. When the sale of products from Biotech Pharm1 becomes a reality within a short time, we will soon be able to fulfill our obligations in the commercial part of the business, where we already have signed agreements worth more than
- The approval of Biotech Pharm1 means that we can soon start the production of biomaterial for export to partners in
When
- The choice of the American OTCQB Venture Market is definitely deliberate. Over time, we have received a number of inquiries from potential investors in the
About
The Company has an ambition to deliver a qualified and standardized product - prepared according to standards that apply in the manufacture of conventional medicine. The
For more information, visit: www.dancann.com
For further information, please contact:
E-mail: jkr@dancann.com
Website: www.dancann.com
Disclaimer
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
https://news.cision.com/dancann-pharma/r/dancann-pharma-a-s--a-strengthened-market-position-after-an-impressive-h2-2022,c3684090
https://mb.cision.com/Main/19875/3684090/1734946.pdf
(c) 2022 Cision. All rights reserved., source